WWW.DISSERS.RU


...
    !

Pages:     | 1 ||

.. , .. , .. , .. , 2007 -X 1 .. , .. , .. ...

-- [ 2 ] --

32. .. - (, ): . .

. . ., 1994.

33. .. :

// 2- . ., 1998. . 35-38.

34. .., .., .., .. . // .

. 1988. 2:166-170.

35. .. .// - , 1993.

36. .. . // . .

1990. 1. . 6-8.

37. O.K., .., . . // // . . .. ., 2003. . 135.

38. .. . // : .

.., .. ̻,2004.. 116.

40. . . : . .., .. ̻, 2004.784 .

41. .., .., .. . , 2001.

42. . . ., 2000.

43. .., .., .., .. // . 1984. 4. . 29-32.

44. .., .. // ., , 1986.

45. Adjadj ., Rubino , Shamsaldim A., Le M.G. et al. The risk of multiple primary breast and thyroid carcinomas. Cancer. 2003;

98(6): 1309-17.

46. Aebi S., Castiglione-Gertsch M. Adjuvant endocrine therapy for very yong patients // Breast 2003 Dec;

12(6): 509-15.

47. Allegra J., Barlock A., Huft K., Lippman M. Changes in multiple or sequential estrogen receptor determinations in breast cancer // Cancer (Philad.) 1980. Vol. 45. P.792-794.

48. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet, July 11, 1886, 104-107.

49. Bonadonna G.Valagussa P The contribution of medicine to the primary treatment of breast cancer. // Cancer Res. 1988. 48, 9.

p. 2314-2324. etal., 1998;

50. Boyle T.J., Boyle J., McNamara et al. Laparoscopic oophorectomy an adjuvant therapy in primary premenopausal breast cancer. // Internathional Conference on adjuvant therapy of primary breast cancer, St. Gallen, Switzerland, 1-4 March, 1995, Anti-Cancer Drugs. 1995. Vol 6, suppl. 2. P. 66.

51. Bruhat M.A., Manhes H., Lagarde N. et al Treatment of ectopic pregnancy by means of laparoscopy. // Fertil. Steril. 1980. Vol.33.

P.411.

52. Cai C, Wang M.A. Clinicopathological analesis of 22 cases of multiple malignant tumors.Clin Med Sci J. 2002 (2):124-6.

53. Chapron C, Querleu D., Bruhat MA: Surgical complications of diagnostic and operaitive gynecological laparoscopy: A series of 29966 cases. Hum Reprod 13:867-1872, 1998.

55. Counsebl R., Bain G. Artificial radiation menopaus: where are the ovaries. // Clin. Oncol. (R. Coll. Radiol.). 1996;

8(4): 250-3.

56. DaoT.L., Sinha D.K., Nemoto ., Patel J. Effect of estrogen and progesterone on cellular replication of human breast tumors. Cancer Res. 42: 359-362, 1982.

57. Dees E.C., Davidson N.E. Ovarian ablation as adjuvant therapy for breast cancer. // Semin. Oncol. 2001 Aug;

28(4): 322-31.

58. Dorffel W.V., Reitzig P., Dorffel Y., Possinger K. Secondary malignant neoplasms in patients with breast cancer Zentralbl Gynacol.

2000;

122(8): 419-27.

59. Dowsett M, Cantwell ., Lai A., et al. Supression of postmenopausal ovarian steroidogenesis with lutensing hormone-releasing hormone agonist goserilin. J. Clin. Endocrinol. Metab. 66: 672-677, 1988.

60. Eeles R.A., Powles T.J. Chemoprevention options for BRCA1 and BRCA2 mutation carriers. J Clim Oncol 2000 Nov 1;

18(21 Suppl):

93S-9S.

61. Featherstone C, Harnet AN.,Ultrasuond localization of the ovaries for radiation - induced of ovarian ablation. // Clin. Oncol. (R. Coll.

Radiol.) 1999;

11(6): 393-7.

62. Fisher ., Carbone P., Econcman S. G. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. // Cancer Res. 1983. 43. P. 1488-92.

63. Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breastand ovarian cancer incidece.

Am. J. Hum. Genet 1995;

57: 1457-1462.

64. Fracchia AA., Farrow JH., DePaloAJ. etal.: Castration for primary inoperable or reccurent breast cancinoma. Surg Gynec Obstet 128:

1226-1234, 65. Hadjisavvas A., Charalambous E.,Adamou A. et al. Hereditary breast and ovarian cancer in Cyprus: identificaition of a founder BRCA2 mutation. Cancer Genet Cytogenet. 2004(2):152-6. 71.

Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breastand ovarian cancer incidece.

Am. J. Hum. Genet 1995;

57: 1457-1462.

66. Haffty B.G, Harrold E., Khan A.J. et al. Outcome of conservatively managed early-onset breast cancer by RCA 12 status. Lancet Apr 27;

359 (9316): 1471-7.

67. Harvey H., Lipton A., Max D., et al. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J.

Clin. Oncol.3: 1068-1072,1985.

69. Hemminki ., Granstrom . Morphological types of breast cancer in family members and multiple primarytumors: is morphology genetically determined Breast Cancer Res. 2002;

4(4): R7.

70. Hoffken K., Kath R. The role of LH-RH analogues in the adjuvant and palliative treatment of // Recent Results Cancer Res. 2000;

153 61-70.

71. Hoogerbrugge N., Bult P., de Widt-Levert L.M., Beex L. V. et al. High prevalence of premalignant lesions in prophylactically removed breast from women at hereditary risk for breast cancer. J Clin Oncol 2003 Jan l;

21(l)41-5.

67. Kaufmann M., Jonat W., Kleeberg U. et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with meta-static breast cancer. J Clin Oncol 7: 1113-1119, 1989.

68. Kolmorgen K. Ovariectomy by laparoscopy. // Zentraebl Gynacol.

1989;

111(9)613-7.

69. Leake R., Laing L., McArdle et al. Soluble and nuclear estrogen receptors status in human breast cancer in relation to prognosis // Brit. J. Cancer. 1981. Vol. 43. P. 67-71.

70. Linell F., Tergrup I., Tennvall-Nittby L., Landberg T. Modified histologic classification for carcinoma of the breast. Prognostic value and relation to effect of adjuvant oophorectomy // Acta oncol.

1987. Vol. 26, N 5. P. 343-348.

71. Liu C. Laparoscopic hysterectomy (personal experience) // References Gynecol. Obstet. 1994. Vol. 2, No.8 P. 69-77.

72. Maas H., Jonat W. Endocrin treatment of advanced breast cancer // RRCR. Endocrine Treatment of Breast Cancer. A new Approch / Ed by B. Henningsen et al. - Berlin, New York: Springer-Verlag, 1980.

P. 102-111.

73. Mage G., Chapron et al. Laparoscopic hysterectomy // Eur. J.

Obstet. Gynecol. Reprod. Med. 1 Vol. 44. P. 25.

74. McGuire W., Chamness G, Fuqua S. Mini-review-estrogen receptor variants in clinical breast cancer. Molecular Endocrinology 5: 1571 1577, 1991.

75. Mirhashemi R., Harlow BL., Gisburg ES.: Predicting rise of complications with gynecologic laparoscopic surgery. Obstet Gynecol. 92:327-331, 1998.

76. Mueller M.D., Dreher E., Eggimann T. Is laparoscopic ovariectomy rational in patients with breast cancer? Surg. Endoscopy. 1998 Dec;

12(12): 1390-2.

78. Mueller M.D., Dreher E., Eggimann T. Is laparoscopic ovariectomy rational in patients with breast cancer? Surg. Endoscopy. 1998 Dec;

12(12): 1390-2.

79. O'Boyle C.J., O'Hanlon D.M. Laparoscopic oophorectomy: a prospective evaluation in premenopausal b.c. with particular reference to incidence and severity of menopausal symptoms. Eur J Surg Oncol. 1996 Oct;

22(5): 491-3.

80. Patel K.R., Boon A.P. Metastatic breast cancer presenting as an ovarian cyst diagnosis by fine needle aspiration cytology.

Cytopatology. 1992;

3(3): 191-5.

81. Pertschuk L, Tobin E.. Gaetjens E. Histocemical assay of estrogen and progesterone receptors in breast cancer. Correlation with biochemical assay and patients response to endocrine therapy // Cancer (Philad.).

1980. Vol. 46. P. 2896-2901.

82. Philips G., Hulka ., Hulka G. Laparoscopic procedurs. The American association of gynacoligic laparoscopists membership survey for 1975 //J. Reprod. Med. 1993. Vol.18. P. 227-232.

83. Pritchard K.I. The best use of adjuvant endocrine treatment // Breast 2003 Dec;

12(6): 497-508.

84. Quan ML, Fey J., et al. Role of laparoscopy in the evaluation of the adnexa in patients with stage IV b.c. Gynecol. Oncol. 2004 Jan;

12(1): 327- 85. Ravaioli A., Bagli L., Zucchini A., Monti F. Prognosis and prediction of response in breast cancer: The current role of the main biological markers // Cell Proliferat. 1998. 31, 3-4. P. 113-126.

86. Reish H., Freifild M. L. Laparoscopic hysterectomy // Gynecol.

Surg 1989. Vol. 5. P. 213-216.

87. Reish H., Freifild M. L. Laparoscopic treatment of tubal pregnancy / / Obstet. Gynecol. 1987. Vol. 69, No. 2. P. 275 - 279.

88. Russo J., Frederick J., Ownby H., Fine G. et al. Predictors of recurens and survival of patients with breast cancer // Amer. J. Clin.

Pathol. 1987.88, 2. P. 123-131.

89. Schally A., Comary-Schally A. Agonist of luteinizing hormone releasing hormone. In: Handbook of chemotherapy in clinical oncology / Ed. by E. Cvitkovic et al., 2 nd ed.., 1993, p. 392-394.

90. Semm K. Hysterectomy via laparotomy or pelvioscopy: a new CASH - method without colpotomy // Geburshilfe Frauenheilkd.

1991. Bd. 51. S. 996-1003.

91. Shapiro H.J., Adler D. Excision of ectopic pregnancy throught the laparoscope //Am. J. Obstet. Gynecol. 1973. Vol. 117. P. 290-291.

93. Shek L.L., Godophy W. Survival with breast cancer: The importance of estrogen receptors quantity // Europ. J. Cancer. 1989. Vol. 25, N2.

P. 243-250.

94. Stein R., Coombes C, Howell A. The basis of hormonal therapy of cancer. In: Oxford Textbook of Oncology / Ed. M. Peckham et al.

Oxford Medical Publication. 1995. p. 629-648.

95. Walker K., Turkes A., Williams M. et al. Preliminary endocrinological evaluation of a sustained-release formulaition of LH-releasing hormone agonist in premenopausal women with advanced breast cancer.J.Endocrin. I l l : 349-353,1986.

Pages:     | 1 ||



2011 www.dissers.ru -

, .
, , , , 1-2 .